Overview

Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tigris Pharmaceuticals
Criteria
Inclusion Criteria:

- ER+ or TN Breast Cancer

- Progression on an aromatase inhibitor if ER+

- Prior treatment with taxane if TN

- 18 years or older

- Adequate organ function

- Measurable lesion

Exclusion Criteria:

- symptomatic pulmonary disease

- brain metastases

- pregnant females